Dr Moskowitz said: “This rapid mobilization of major medical centers across the United States reflects the urgent need to treat the very large numbers of people in hospital intensive care units suffering with COVID-19 ARDS and requiring ventilation. We expect quick enrollment in this trial to determine whether remestemcel-L can reduce mortality in these patients."
Ann: First Patients Dosed in Phase 2/3 Trial for COVID-19 ARDS, page-20
-
- There are more pages in this discussion • 169 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.25 |
Change
-0.053(4.02%) |
Mkt cap ! $1.432B | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.30 | $1.17 | $16.47M | 13.35M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 86330 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.26 | 91990 | 8 |
View Market Depth
| Last trade - 14.07pm 24/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |